The mTOR signaling cascade, which is poorly controlled in LAM cells because of changes in TSC1/TSC2, activates downstream effectors, including 4E-binding protein 1 and ribosomal protein S6 kinase beta-1. The gene discussed is MTOR; the disease is lymphangioleiomyomatosis.